Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview

Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.

More from Archive

More from Pink Sheet